Hepatic Cell News Volume 7.43 | Nov 17 2023

    By
    Jamie Kang
    -
    0
    10







    2023-11-17 | HCN 7.43


    Hepatic Cell News by STEMCELL Technologies
    Vol. 7.43 – 17 November, 2023
    TOP STORY

    Loss of SLC27A5 Activates Hepatic Stellate Cells and Promotes Liver Fibrosis via Unconjugated Cholic Acid

    Scientists demonstrated that solute carrier family 27 member 5 (SLC27A5), an enzyme involved in bile acids metabolism, was substantially downregulated in the liver tissues of patients with cirrhosis and fibrosis mouse models.
    [Advanced Science]

    Full Article
    In this webinar on hepatic organoids review the biological characteristics and practical considerations of adding organoids to your research.
    PUBLICATIONSRanked by the impact factor of the journal

    Melanoma Differentiation Associated Gene-9/Syndecan Binding Protein Promotes Hepatocellular Carcinoma

    To unravel the function of MDA‐9 in HCC, investigators generated and characterized a transgenic mouse with hepatocyte‐specific overexpression of MDA‐9.
    [Hepatology]

    AbstractGraphical Abstract

    BRISC Is Required for Optimal Activation of NF-κB in Kupffer Cells Induced by LPS and Contributes to Acute Liver Injury

    Researchers investigated the pathophysiological role of BRCC3 isopeptidase complex (BRISC) in acute liver failure using a mice model induced by D-galactosamine plus lipopolysaccharide.
    [Cell Death & Disease]

    Full Article

    USP11 Potentiates HGF/AKT Signaling and Drives Metastasis in Hepatocellular Carcinoma

    Scientists demonstrated that the USP11 expression was dramatically upregulated in HCC tissues and cell lines. Increased USP11 expression was closely associated with tumor number, vascular invasion, and poor prognosis.
    [Oncogene]

    Abstract

    Synergistic Antitumor Efficacy of Aspirin plus Lenvatinib in Hepatocellular Carcinoma via Regulating of Diverse Signaling Pathways

    Investigators evaluated the antitumor efficacy and safety of combination therapy involving aspirin and lenvatinib in HCC. Through in vitro and in vivo assays, they demonstrated that this combination yielded stronger antitumor effects compared to lenvatinib or aspirin monotherapy.
    [Cell Death Discovery]

    Full Article

    LASS2 Enhances p53 Protein Stability and Nuclear Import to Suppress Liver Cancer Progression through Interaction with MDM2/MDMX

    LASS2 overexpression was found to significantly inhibit proliferation, migration, invasion and induce apoptosis in hepatoma cells with wild-type and mutated p53.
    [Cell Death Discovery]

    Full Article

    Cytokine Profile and Viral Diversity in the Early Seronegative Stage of Community-Acquired Hepatitis C Virus (HCV) Infection

    Investigators analyzed factors associated with outcome during the preclinical seronegative phase of community-acquired Hepatitis C virus infection.
    [Scientific Reports]

    Full Article

    Effects of Green Light-Emitting Diode Irradiation on Hepatic Differentiation of Hepatocyte-Like Cells Generated from Human Adipose-Derived Mesenchymal Cells

    Scientists investigated the effect of green LED irradiation on the differentiation of adipocyte-derived mesenchymal cells into hepatocyte-like cells and the mechanism of its action.
    [Scientific Reports]

    Full Article

    IGFBP2 Drives Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma via Activating the Wnt/β-Catenin Pathway

    Researchers presented evidence highlighting the influence exerted by insulin-like growth factor-binding protein 2 (IGFBP2) as a potent oncogene driving the malignant phenotype.
    [Infectious Agents And Cancer]

    Full Article
    View tips on how to organize your lab bench space.
    REVIEWS

    The Material World of 3D-Bioprinted And Microfluidic-Chip Models of Human Liver Fibrosis

    The recent and cutting-edge biomaterials used for creating in vitro models of human liver fibrosis are revised, in combination with cells, bioprinting and/or microfluidics.
    [Advanced Materials]

    Abstract
    INDUSTRY AND POLICY NEWS

    Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase II Study of Advanced (F3) MASH Liver Disease

    Hepion Pharmaceuticals, Inc. announced additional efficacy data for rencofilstat, its lead drug candidate for the treatment of metabolic dysfunction-associated steatohepatitis, fibrotic diseases, hepatocellular carcinoma, and other chronic diseases.
    [Hepion Pharmaceuticals, Inc.]

    Press Release
    FEATURED EVENT

    Cell Bio 2023

    December 2 – 6, 2023
    Boston, Massachusetts, United States

    > See All Events

    JOB OPPORTUNITIES

    PhD Studentship – Epigenetic Regulation of Cancer Metabolism

    Nottingham Trent University – Nottingham, England, United Kingdom

    Research Assistant – Epigenetics

    Babraham Institute – Cambridge, England, United Kingdom

    PhD Student – Cancer Science

    University of Oxford – Oxford, England, United Kingdom

    Postdoctoral Researcher – Cancer Bioinformatics and Immunotherapies

    Armenian Bioinformatics Institute – Yerevan, Armenia

    Postdoctoral Scientist – Cancer Research Cluster

    Cedars-Sinai – Los Angeles, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Logo for the social media website X